Sino Biopharmaceutical Limited reported unaudited revenue results for the third quarter and nine months ended September 30, 2022. In the third quarter 2022, the Group recorded revenue (unaudited) of approximately RMB 7,473.31 million, an increase of approximately 21.3% over the same period last year.
In the first three quarters 2022, the Group recorded revenue (unaudited) of approximately RMB 22,667.04 million, an increase of approximately 10.5% over the same period last year.